21 January 2021
Splice Bio appoints Jean-Philippe Combal as Chairman of the Board of Directors
BARCELONA, January 21, 2021 – Splice Bio, a gene therapy company based on technology developed in the Muir Lab at Princeton University, announced today that it has appointed Jean-Philippe Combal as Chairman of its Board of Directors. Dr. Combal is a proven senior executive and biotechnology entrepreneur with 30 years of experience in the pharma & biotech industry and particularly in the field of gene therapy.
“Jean-Philippe’s experience developing innovative products and building science-driven companies will be invaluable to Splice Bio as we advance towards our goal of bringing novel gene therapies to patients suffering from genetic diseases caused by large genes,” said Miquel Vila-Perelló, Ph.D., CEO of Splice Bio. “His phenomenal experience and track record in bringing gene therapy products throughout development will be crucial as we embark on developing a pipeline based on our disruptive platform technology. I welcome Jean-Philippe to our team and look forward to working together with him to bring these gene therapies to patients.”
“It is an honor to be invited to be Chairman of Splice Bio which has developed a powerful AAV-intein gene therapy platform with the potential to treat diseases for which no therapeutic option is available today” said Dr. Combal “Splice Bio has assembled a fantastic team with expertise across protein engineering and gene therapy, and I look forward to working closely with the team and the rest of the Board and their goal of expanding the targets of gene therapy based approaches to treat currently incurable diseases.”
Jean-Philippe Combal is a senior executive and biotech entrepreneur who has built companies in the biotech industry from creation with significant fund raising with VCs, IPO and M&A. He currently serves as Chief Executive Officer & Co-founder of Vivet Therapeutics. Prior to that, Dr. Combal served as Chief Operating Officer of GenSight Biologics; Strategic Therapeutic Area Leader at Galderma International; Vice President, Strategic Marketing for the Ophthalmic Division of Fovea-Sanofi, and Vice President, Director of Development at Fovea, where he was instrumental in the development of all products leading to Fovea’s acquisition by Sanofi in 2009. Dr. Combal holds a Pharm.D. and Ph.D. from Paris XI and Paris V University, respectively, and a business degree from ESCP Strategic Marketing & General Management Program from CEDEP-INSEAD.
About Splice Bio
Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company has developed a proprietary, 3rd-generation intein platform that addresses two existing limitations of adeno-associated viruses (AAVs) as vectors for gene therapy, both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted. The company is backed by Ysios Capital, Asabys Partners and Caixa Capital Risc. For additional information, please visit www.splice.bio.